 |
 |
 |
||||||
 |
||||||||
 |
 |
 |
 |
|||||
 |
 |
 |
|
|||||
|
|
|
|
|
|
|
|
|
 |
 |
|
 |
2006 Press Archive | |
|
2005 Press Archive | |
|
2004 Press Archive | |
|
2002 Press Archive | |
|
2001 Press Archive | |
|
2000 Press Archive | |
|
|
|
Sangamo BioSciences Announces Third-Quarter 2003 Teleconference
RICHMOND, Calif., Oct 21, 2003 /PRNewswire-FirstCall via COMTEX/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its third-quarter 2003 financial results on Tuesday, October 28, 2003 after the market closes. The press release will be followed by a conference call at 2:00 p.m. PST, which will be open to the public. During the conference call, the company will review the financial results and discuss other business matters.
The conference call dial-in numbers are 800-730-7991 for domestic callers and 706-634-7552 for international callers. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 5:00 p.m. PST on October 28, 2003 to 9:00 p.m. PST on November 4, 2003. The conference call replay numbers for domestic and international callers are 800-642-1687 and 706-645-9291 respectively. The conference ID number for the replay is 3584310.
About Sangamo
Sangamo Biosciences, Inc is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and repair. The company’s most advanced therapeutic development program involves the use of transcription factors for the treatment of peripheral arterial disease. Other therapeutic development programs are focused on ischemic heart disease, cancer, neuropathic pain, and monogenic diseases. Sangamo’s core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP-Nucleases (ZFNs) for therapeutic gene correction as a treatment and possible cure for a variety of monogenic diseases such as severe combined immunodeficiency (SCID), sickle cell anemia (SCA) and chronic granulatomous disease. For more information about Sangamo, visit the company’s web site at www.sangamo.com.
This press release may contain forward-looking statements based on Sangamo’s current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs and applications of Sangamo’s ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo’s ability to develop commercially viable products and technological developments by our competitors. See the company’s SEC filings, and in particular, the risk factors described in the company’s Annual Report on Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.
SOURCE Sangamo BioSciences, Inc.
Elizabeth Wolffe, Ph.D. of Sangamo Biosciences, Inc.,
+1-510-970-6000, ext. 271, or ewolffe@sangamo.com
back to top
|
Contact |  |
Careers | |
Site Map | |
Legal | |
Glossary | |
|
|
|
|
|
|
|